REN and COVID-19: Increases were also seen in C01 (cardiac therapy) and C02 (antihypertensive drugs), while usage of C09 (agents acting on the renin–angiotensin system (RAS)) and C10 (lipid-modifying agents) declined from pre-COVID to acute COVID-19, followed by a subsequent increase to baseline use in the post-infection phase.